GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,481.50GBp
21 Nov 2014
Price Change (% chg)

4.50p (+0.31%)
Prev Close
1,477.00p
Open
1,482.00p
Day's High
1,490.00p
Day's Low
1,469.00p
Volume
9,273,269
Avg. Vol
9,307,379
52-wk High
1,709.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.51
Market Cap (Mil.): £71,792.97
Shares Outstanding (Mil.): 4,860.73
Dividend: 19.00
Yield (%): 5.42

Financials

  GSK.L Industry Sector
P/E (TTM): 17.21 38.05 39.20
EPS (TTM): 0.86 -- --
ROI: 16.65 17.86 17.16
ROE: 75.96 18.61 18.09
Search Stocks

No safety concerns yet in trials of GSK's Ebola vaccine

LONDON - Almost 200 people have received GlaxoSmithKline's experimental Ebola vaccine in trials in the United States, Britain, Mali and Switzerland, and the safety data so far are "very satisfactory", scientists said on Monday.

17 Nov 2014

No safety concerns yet in trials of GSK's Ebola vaccine

LONDON, Nov 17 - Almost 200 people have received GlaxoSmithKline's experimental Ebola vaccine in trials in the United States, Britain, Mali and Switzerland, and the safety data so far are "very satisfactory", scientists said on Monday.

17 Nov 2014

Corruption tars drug industry drive to improve access for poor

* Top drugmakers doing more for world's poor, report finds

16 Nov 2014

BRIEF-GSK to fund research into non-communicable diseases in Sub-Saharan Africa

* GSK launches first call for proposals for research in to non-communicable diseases in Sub-Saharan Africa

14 Nov 2014

Exclusive: Apollo to bid for GlaxoSmithKline's mature drugs - sources

LONDON - Apollo Global Management is planning to bid for all GlaxoSmithKline's mature drugs, joining an auction expected to value the business at more than $3 billion, according to four people familiar with the process.

13 Nov 2014

FTSE ends slightly higher, RSA slips on premium concerns

LONDON, Nov 6 - Britain's top share index surrendered most of its gains and ended slightly higher on Thursday, with RSA leading insurers lower on weak premiums and drugmaker GlaxoSmithKline slipping after trading without the attraction of its latest dividend.

06 Nov 2014

FTSE steadies after gaining on Draghi's comments

LONDON, Nov 6 - Britain's top share steadied in late trading on Thursday after surrendering earlier gains, with RSA leading insurers lower on weak premiums and drugmaker GlaxoSmithKline slipping after trading without the attraction of its latest dividend.

06 Nov 2014

FTSE steadies as stronger retailers offset fall in pharma stocks

LONDON, Nov 6 - Britain's top share index steadied on Thursday as drugmakers AstraZeneca and GlaxoSmithKline weighed, offsetting gains for retailers and an encouraging update from grocer WM Morrisons.

06 Nov 2014

Glaxo scientists work to rebuild cancer line-up, funding uncertain

PHILADELPHIA - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.

05 Nov 2014

Glaxo scientists work to rebuild cancer line-up, funding uncertain

PHILADELPHIA, Nov 5 - When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.

05 Nov 2014

Earnings vs. Estimates

Search Stocks